DongKook Pharmaceutical Co (XKRX:086450) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is DongKook Pharmaceutical Co Debt-to-Equity?

DongKook Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0 Mil. DongKook Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0 Mil. DongKook Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩555,990 Mil. DongKook Pharmaceutical Co's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for DongKook Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

XKRX:086450' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.14 Max: 0.22
Current: 0.14

During the past 13 years, the highest Debt-to-Equity Ratio of DongKook Pharmaceutical Co was 0.22. The lowest was 0.02. And the median was 0.14.

XKRX:086450's Debt-to-Equity is ranked better than
66.98% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs XKRX:086450: 0.14

DongKook Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for DongKook Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DongKook Pharmaceutical Co Debt-to-Equity Chart

DongKook Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.17

0.22

0.13

0.14

DongKook Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.13	0.13	0.13	0.14	-

Competitive Comparison of DongKook Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, DongKook Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DongKook Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DongKook Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where DongKook Pharmaceutical Co's Debt-to-Equity falls into.

DongKook Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

DongKook Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(56485.207	+	20218.629)	/	544694.047
	=	0.14

DongKook Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	555989.63
	=	0.00

DongKook Pharmaceutical Co (XKRX:086450) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

DongKook Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of DongKook Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

DongKook Pharmaceutical Co (XKRX:086450) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DongKook Pharmaceutical Co Ltd (XKRX:086450) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Dongkook Building 997-8 Daechi 3-dong, Kangnam-gu, Seoul, KOR, 135-502

Website

http://www.dkpharm.co.kr

DongKook Pharmaceutical Co Ltd is a part of the healthcare industry based in Korea. Being a pharmaceutical company, its activities are focused on the research and development of drugs. The company produces superior medicines used favorably by consumers such as Madecassol, which is a drug for wounds and Oramedy, which is a drug for treating stomatitis. It also owns a prefilled syringe system in its second factory, through which it produces various kinds of ultramodern injection agents.

DongKook Pharmaceutical Co (XKRX:086450) Headlines

No Headlines